Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T21:08:46.508Z.
Calculation as of: 2026-10-06T21:08:46.508Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 76451fd983189bd376b55241b8a4b850ffcaa8def2b2c0e687122d8ae3ae7442
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Verrica Pharmaceuticals Inc.
Market Cap
$72.32M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$72.83M
Price/FCF Ratio
N/A
TTM Avg
1291.26
3Y Avg
1291.26
5Y Avg
1291.26
Market Cap
$69.61M
Price/FCF Ratio
N/A
TTM Avg
17.09
3Y Avg
24.44
5Y Avg
36.17
Market Cap
$68.90M
Price/FCF Ratio
3.52
TTM Avg
11.66
3Y Avg
7.20
5Y Avg
7.81
Market Cap
$75.95M
Price/FCF Ratio
4.56
TTM Avg
5.17
3Y Avg
25.10
5Y Avg
25.10
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | $72.32M | N/A | N/A | N/A | N/A |
| MindWalk Holdings Corp. (HYFT)vs › | $72.83M | N/A | 1291.26 | 1291.26 | 1291.26 |
| Hyperfine, Inc. (HYPR)vs › | $73.27M | N/A | N/A | N/A | N/A |
| Gain Therapeutics, Inc. (GANX)vs › | $71.23M | N/A | N/A | N/A | N/A |
| Tiziana Life Sciences Ltd (TLSA)vs › | $70.63M | N/A | N/A | N/A | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $69.61M | N/A | 17.09 | 24.44 | 36.17 |
| Pulmonx Corporation (LUNG)vs › | $75.18M | N/A | N/A | N/A | N/A |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.90M | 3.52 | 11.66 | 7.20 | 7.81 |
| SkinHealth Systems Inc. (SKIN)vs › | $75.95M | 4.56 | 5.17 | 25.10 | 25.10 |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | 0.54 | 0.74 | 0.74 | 0.74 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
